Stocklytics Platform
Asset logo for symbol DYN
Dyne Therapeutics
DYN56
$11.65arrow_drop_down2.01%-$0.24
Asset logo for symbol DYN
DYN56

$11.65

arrow_drop_down2.01%
Key Stats
Open$11.46
Prev. Close$11.90
EPS-3.37
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range11.38
12.08
52 Week Range6.40
47.45
Ratios
Revenue-
EBITDA Margin %-
EPS-3.37
Fundamentals
RPS-
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

DYN-
US Healthcare Sector-
US Market-
warning

DYN / Market

DYN lose to the US Market which returned 0.03% over the last twenty four hours.
warning

DYN / Healthcare Sector

DYN lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Dyne Therapeutics (DYN) Statistics

Dyne Therapeutics Inc (DYN) is a leading biotechnology company that specializes in developing innovative therapies for patients with serious muscle diseases. The company is focused on advancing its proprietary technology platform, which utilizes targeted muscle delivery to address the underlying genetic causes of these diseases. With a team of world-class scientists and experts in the field, Dyne Therapeutics is at the forefront of pioneering research and development in the muscle disease space.
When it comes to valuation metrics, Dyne Therapeutics Inc has shown impressive growth. The company's current market capitalization stands at $X.XX billion, and its stock price has experienced a steady rise over the past year. This positive performance is a reflection of the market's confidence in Dyne Therapeutics' potential to revolutionize the treatment of muscle diseases.
add Dyne Therapeutics  to watchlist

Keep an eye on Dyne Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Dyne Therapeutics (DYN) stock's performance compared to its sector and the market over the past year?

Over the past year, Dyne Therapeutics (DYN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Dyne Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Dyne Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Dyne Therapeutics (DYN) stock?

The PE ratio for Dyne Therapeutics (DYN) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Dyne Therapeutics (DYN) stock?

The Earnings Per Share (EPS) for Dyne Therapeutics (DYN), calculated on a diluted basis, is -$3.37. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Dyne Therapeutics (DYN) stock?

The operating margin for Dyne Therapeutics (DYN) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Dyne Therapeutics (DYN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Dyne Therapeutics (DYN) is -$342.21M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Dyne Therapeutics (DYN) have?

Dyne Therapeutics (DYN) has a total debt of $23.99M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$411.46M.

Take Your Investments to a Whole New Level